Streetbeat News

ENZC

Enzolytics Inc

Employees

Open

0.00

Mkt cap

4.8M

Volume

103K

High

0.00

P/E Ratio

N/A

52-wk high

0.03

Low

0.00

Div yield

N/A

52-wk low

0.00

Enzolytics, Inc. has signed a business combination agreement for the sale of its operating subsidiaries, Biogenysis, Inc. and Virogentics Inc., to Sagaliam Acquisition Corp in a deal valued at $450 million. The combined company is expected to trade on NASDAQ. The deal will provide additional funding to Biogenysis and Virogentics, enabling the final development of numerous therapeutics.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:15 pm

Sagaliam Acquisition Corp. (SAGA) has amended its non-binding term sheet for the purchase of Biogenysis, Inc. (BGEN) and Virogentics Inc. (VIRO), subsidiaries of Enzolytics Inc. (ENZC), raising the combined purchase price to $450M. Sagaliam plans to raise additional capital through a PIPE transaction, which will be used to fund clinical trials and drug discovery efforts. New board members have also been announced.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 1:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.